Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments, specifically Scalp Micropigmentation and potentially Minoxidil, Finasteride, or RU58841.

Hair cloning was predicted to be a baldness cure within 3-4 years in 2004, but it has not materialized. Users express frustration and skepticism about the delay.

The conversation discusses unconventional and satirical ideas for hair regrowth, including using umbilical cord cells, stem cells, and other humorous suggestions. It concludes with recommendations for more traditional methods like hair transplants or hair systems.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

A person struggling with hair loss is using treatments like dutasteride, oral minoxidil, and has had a hair transplant but remains deeply unhappy. Others suggest alternative treatments, acceptance, and focusing on other life aspects, emphasizing mental health and therapy.

A 31-year-old man has been using Dutasteride since 2022, alongside topical Minoxidil, with positive results and no issues. His new healthcare provider expressed concerns about long-term Dutasteride use and suggested alternatives like oral Minoxidil and Spironolactone, but the patient is hesitant to change a successful routine.

Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

A user reported noticeable hair regrowth using a 272 diode red light therapy hat over 11 months without Minoxidil or Finasteride. Opinions vary on its effectiveness compared to traditional treatments, with some suggesting combining therapies for better results.

South Korea's president is advocating for hereditary hair loss to be covered by national health insurance due to its impact on mental health and daily functioning. The discussion highlights the societal pressure in South Korea regarding appearance and the potential benefits of treating hair loss to improve mental health.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

George Clooney likely had a hair transplant, as many Hollywood actors do to maintain their appearance. Treatments like finasteride and hair transplants are common among celebrities to combat hair loss.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

Significant hair improvement was achieved using 1.25mg finasteride and 5mg oral minoxidil daily, with no side effects. The user increased the minoxidil dosage to 7.5mg after noticing minor thinning and plans to continue the routine.

Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.

David Dobrik uses Minoxidil and possibly Finasteride for hair loss but applies them incorrectly. Users suggest he consider surgery due to his financial capability.

Users discussed their experiences with hair loss treatments, primarily finasteride (Fin) and dutasteride (Dut), often combined with minoxidil (Min) and derma rolling. Many reported mixed results, with some seeing slowed hair loss and others experiencing side effects or minimal improvement.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

A young person is distressed about rapid hair loss despite using finasteride and recently starting oral minoxidil. Many suggest continuing treatment, considering dutasteride, and seeking therapy for mental health support.

A 30-year-old man shares his successful hair loss protocol, which includes finasteride, Nizoral shampoo, low-level laser therapy, microneedling, and past use of oral minoxidil. He plans to consider dutasteride and possibly hair transplants in the future, while advising caution with crown transplants before age 35.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

Developing new hair loss treatments is challenging due to the complexity and cost of trials, and a permanent cure is unlikely soon. Current treatments like Minoxidil and finasteride are used continuously because hair loss is progressive, and future possibilities include gene editing and hair cloning.

High sugar diets may worsen hair loss by increasing 5α-reductase activity and androgen levels, especially in women with PCOS. A low sugar diet might reduce scalp DHT levels, similar to finasteride, but genetics also significantly influence hair loss.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.